A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-Line Rituximab-Chemotherapy.
Phase of Trial: Phase III
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms PILLAR-2
- Sponsors Novartis; Novartis Pharmaceuticals
- 23 Aug 2016 Status changed from active, no longer recruiting to completed.
- 19 Aug 2016 This trial was completed in Czech Republic (end date: 15-06-2016), according to European Clinical Trials Database.
- 13 Aug 2016 This trial was completed in Hungary (end date: 15-06-2016), according to European Clinical Trials Database.